Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent to participate in the trial * Age 18 to 75 years, any sex * Histologically or cytologically confirmed nasopharyngeal carcinoma, with clinically diagnosed liver and/or lung metastases * Primary nasopharyngeal tumor cured after curative treatment, with no lymph node metastasis and no metastases outside the liver and lung (metachronous metastasis: distant metastasis detected at least 6 months after curative treatment of the primary tumor) * No more than 5 liver and/or lung metastases, each 3 cm or smaller in diameter * Liver and/or lung metastases amenable to ablation * ECOG performance status 0 or 1 * Adequate hematologic and organ function: absolute neutrophil count ≥1.5×10\^9/L; hemoglobin ≥70 g/L; platelet count ≥50×10\^9/L; white blood cell count ≥3.0×10\^9/L; serum albumin ≥28 g/L; total bilirubin ≤3.0 mg/dL; AST and ALT ≤5×ULN; serum creatinine ≤1.5×ULN; INR ≤2.3 (without anticoagulant therapy) * No prior systemic therapy for metastatic disease (e.g., gemcitabine plus cisplatin chemotherapy or PD-1 inhibitor) Exclusion Criteria: * History of hypersensitivity or intolerance to any study drug * Severe hepatic insufficiency, pulmonary fibrosis, or pulmonary hypertension * Poorly controlled infectious or radiation-induced inflammation around the lesion, skin infection at the puncture site, systemic infection, or fever \>38.5 °C * Estimated life expectancy less than 3 months * Poorly controlled malignant pleural effusion * Clinically significant bleeding within 30 days before study entry * Uncorrectable coagulopathy or marked hematologic abnormality with evident bleeding tendency * Severe hepatic, renal, cardiac, pulmonary, or cerebral dysfunction; severe anemia, dehydration, or nutritional/metabolic disturbance that cannot be corrected in the short term; left ventricular ejection fraction \<45% * History of congenital long QT syndrome, or corrected QT interval \>480 ms (Fridericia) * Psychiatric disorder in an active episode * Poorly controlled hypertension: systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg * Urine protein ≥1 g/24 h (participants with ≥1+ proteinuria on dipstick must have 24-hour urine protein measured); prior organ transplantation * Anticoagulant and/or antiplatelet therapy (except novel oral anticoagulants such as dabigatran and rivaroxaban) not discontinued for more than 5-7 days before ablation * Other malignancy within the previous 3 years or concurrently * Prior gemcitabine plus cisplatin chemotherapy or PD-1 inhibitor therapy * Any other condition that, in the investigator's judgment, makes the patient unsuitable for the trial